| Literature DB >> 29552196 |
Zhanpeng Luo1,2, Dawei Li1,2, Xiaobo Luo2, Litao Li2, Suxi Gu2, Long Yu2, Yuanzheng Ma1,2.
Abstract
The present study aimed to determine the mechanisms of action of curcumin in osteosarcoma. Human osteosarcoma U-2 OS cells was purchased from the Cell Bank of the Chinese Academy of Sciences. RNA sequencing analysis was performed for 2 curcumin-treated samples and 2 control samples using Illumina deep sequencing technology. The differentially expressed genes were identified using Cufflink software. Enrichment and protein-protein interaction network analyses were performed separately using cluster Profiler package and Cytoscape software to identify key genes. Then, the mRNA levels of key genes were detected by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in U-2 OS cells. Finally, cell apoptosis, proliferation, migration and invasion arrays were performed. In total, 201 DEGs were identified in the curcumin-treated group. EEF1A1 (degree=88), ATF7IP, HIF1A, SMAD7, CLTC, MCM10, ITPR1, ADAM15, WWP2 and ATP5C1, which were enriched in 'biological process', exhibited higher degrees than other genes in the PPI network. RT-qPCR demonstrated that treatment with curcumin was able to significantly increase the levels of CLTC and ITPR1 mRNA in curcumin-treated cells compared with control. In addition, targeting ITPR1 with curcumin significantly promoted apoptosis and suppressed proliferation, migration and invasion. Targeting ITPR1 via curcumin may serve an anticancer role by mediating apoptosis, proliferation, migration and invasion in U-2 OS cells.Entities:
Keywords: RNA sequencing; anticancer role; curcumin; differentially expressed gene; osteosarcoma
Year: 2018 PMID: 29552196 PMCID: PMC5840671 DOI: 10.3892/ol.2018.8032
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Primer sequences for specific genes.
| Name of primer | Primer sequences (5′-3′) |
|---|---|
| EEF1A1-hf | TGCCTGGGTCTTGGATAAAC |
| EEF1A1-hr | GCCTGAGATGTCCCTGTAAT |
| ATF7IP-hf | TTCCGCCCCAAAAGATTCAGA |
| ATF7IP-hr | CTGCTTCAAGTTGCTGACGATC |
| HIF1A-hf | ACTTCTGGATGCTGGTGATT |
| HIF1A-hr | GTTCAAACTGAGTTAATCCC |
| SMAD7-hf | ACCTTAGCCGACTCTGCGAACT |
| SMAD7-hr | TTTCAGCGGAGGAAGGCACA |
| CLTC-hf | TTGAATACGGTTGCTCTTGT |
| CLTC-hr | ATGCCAGTCAGAAGTAACCA |
| MCM10-hf | CTTTGAATACGGTTGCTCTT |
| MCM10-hr | GTACGGTAATTGATAATCTGG |
| ITPR1-hf | CCTGGTTGATGATCGTTGTGTT |
| ITPR1-hr | GCTTTTGGGCAGAGTAGCGGTT |
| ADAM15-hf | ATCCCTGCTGTGATTCTTTGACC |
| ADAM15-hr | TGGGCATAGGAGGCACAACG |
| WWP2-hf | CCCCGAATCCCAACACGACT |
| WWP2-hr | TCCCATCCAGCAGGCAGAGC |
| ATP5C1-hf | AAAAGCGAGGTTGCTACACT |
| ATP5C1-hr | ATGACTGACGCATCTCCAAA |
| GAPDH-hf | TGACAACTTTGGTATCGTGGAAGG |
| GAPDH-hr | AGGCAGGGATGATGTTCTGGAGAG |
EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease domain 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1; h, human; f, forward; r, reverse.
Results from quality control and assembly of sequencing data.
| ID | Group | Number of cleaned paired-end reads | Number of aligned pair reads |
|---|---|---|---|
| 14710C-1 | Control | 11,660,638 | 8,129,145 |
| 14710C-2 | Control | 12,351,701 | 8,531,536 |
| 14710C-5 | Curcumin | 13,820,514 | 8,368,710 |
| 14710C-6 | Curcumin | 11,927,581 | 8,797,461 |
GO terms enriched for upregulated and downregulated genes.
| Go term | Description | Gene number | FDR | Gene symbol |
|---|---|---|---|---|
| Upregulated DEGs | ||||
| GO: 8150 | Biological process | 94 | 3.75×10-6 | EEF1A1, ATF7IP, SMAD7, CLTC, MCM10 |
| GO: 16043 | Cellular component organization | 41 | 1.95×10-2 | ATF7IP, SMAD7, CLTC, CDH4, RTN3 |
| GO: 71840 | Cellular component organization or biogenesis | 41 | 2.08×10-2 | ATF7IP, SMAD7, CLTC, CDH4, RTN3 |
| Downregulated DEGs | ||||
| GO: 8150 | Biological process | 64 | 8.18×10-4 | HIF1A, ADAM15, ARFRP1, AKAP9, ABI2 |
| GO: 50896 | Response to stimulus | 40 | 5.62×10-3 | HIF1A, ADAM15, ARFRP1, AKAP9, MALT1 |
| GO: 51716 | Cellular response to stimulus | 34 | 5.62×10-3 | HIF1A, ARFRP1, AKAP9, MALT1, MGLL |
| GO: 9987 | Cellular process | 59 | 5.62×10-3 | HIF1A, ADAM15, ARFRP1,RBM5, PFDN6 |
| GO: 7165 | Signal transduction | 29 | 1.03×10-2 | HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2 |
| GO: 23052 | Signaling | 30 | 1.79×10-2 | HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2 |
| GO: 44700 | Single organism signaling | 30 | 1.79×10-2 | HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2 |
| GO: 7154 | Cell communication | 30 | 1.89×10-2 | HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2 |
| GO: 71704 | Organic substance metabolic process | 46 | 1.89×10-2 | HIF1A, ADAM15, ARFRP1,GSTO2, ADK |
| GO: 44238 | Primary metabolic process | 45 | 1.89×10-2 | HIF1A, ADAM15, ARFRP1,GSTO2, ADK |
| GO: 50789 | Regulation of biological process | 43 | 2.04×10-2 | HIF1A, ARFRP1, AKAP9, ABI2, RBM5 |
| GO: 50794 | Regulation of cellular process | 41 | 2.55×10-2 | HIF1A, ARFRP1, AKAP9, ABI2, RBM5 |
| GO: 44699 | Single-organism process | 53 | 2.98×10-2 | HIF1A, ADAM15, ARFRP1, AKAP9, ABI2 |
| GO: 1568 | Blood vessel development | 6 | 4.65×10-2 | HIF1A, ADAM15, ANKRD17, RAPGEF1, NPRL3, NRP1 |
| GO: 43170 | Macromolecule metabolic process | 38 | 4.98×10-2 | HIF1A, ADAM15, ABI2, RBM5, PFDN6 |
GO, Gene Ontology; DEGs, differentially expressed genes; FDR: false discovery rate; EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease domain 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1; RTN3, reticulon 3; GSTO2, glutathione S-transferase Omega 2; ADK, adenosine kinase; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; RAP1GAP2, RAP1 GTPase activating protein 2; AKAP9, A-kinase anchoring protein 9; MGLL, monoglyceride lipase; PFDN6, prefoldin subunit 6; RBM5, RNA binding motif protein 5; ABI2, Abl interactor 2; NRP1, neuropilin 1; NPRL3, nitrogen permease regulator 3-like protein 3.
Figure 1.Protein-protein interaction network that involves the identified differentially expressed genes. Red and green nodes represent upregulated and downregulated genes, respectively. Blue nodes indicate the genes with no significant change in expression.
Figure 2.Treatment with curcumin significantly increases the mRNA levels of CLTC and ITPR1 and decreases the mRNA levels of ADAM15 in curcumin-treated cells compared with dimethyl sulfoxide-treated and control cells, *P<0.01 compared with control cells, #P<0.01 compared with dimethyl sulfoxide-treated cells. EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1; Con, control; DMSO, dimethyl sulfoxide.
Figure 3.ITPR1 is significantly decreased in cells transferred with ITPR1 siRNA sequences in comparison with negative control cells and control cells. ***P<0.001 when comparing the siRNA group with the negative control and control cells (compared separately). ITPR1, inositol 1,4,5-triphosphate receptor type 1; si, small interfering; con, control.
Figure 4.Treatment with curcumin significantly suppresses proliferation of U-2 OS cells, and the effect of curcumin-mediated suppression decreases following knockdown of inositol 1,4,5-triphosphate receptor type 1. *P<0.05, compared with negative control cells and control cells; #P<0.01, compared with negative and curcumin-treated cells. si, small interfering; con, control.
Figure 5.Treatment with curcumin significantly promotes apoptosis of U-2 OS cells, while the apoptotic rate of U-2 OS cells transfected with inositol 1,4,5-triphosphate receptor type 1 siRNA sequences were significantly decreased. *P<0.05, compared with negative control cells and control cells; #P<0.05, compared with negative and curcumin-treated cells. si, small interfering; con, control.
Figure 6.Treatment with curcumin significantly inhibits cell migration, while ITPR1 interference promotes migration of U-2 OS cells (magnification, ×200). *P<0.01, compared with negative control cells and control cells (Note: for siRNA treated cells at 12 h, the *P<0.01 is compared with control cells); #P<0.05, compared with negative and curcumin-treated cells. si, small interfering; con, control. ITPR1, inositol 1,4,5-triphosphate receptor type 1.
Figure 7.Treatment with curcumin significantly inhibits invasion of U-2 OS cells, and inositol 1,4,5-triphosphate receptor type 1 interference relieves the inhibitory effect of curcumin on cell invasion (magnification, ×200). *P<0.05 compared with negative control cells and control cells; #P<0.05 compared with negative and curcumin-treated cells. si, small interfering; con, control.